|
1
|
Doherty JA, Peres LC, Wang C, Way GP,
Greene CS and Schildkraut JM: Challenges and opportunities in
studying the epidemiology of ovarian cancer subtypes. Curr
Epidemiol Rep. 4:211–220. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lheureux S, Gourley C, Vergote I and Oza
AM: Epithelial ovarian cancer. Lancet. 393:1240–1253. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reid BM, Permuth JB and Sellers TA:
Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sizemore GM, Pitarresi JR, Balakrishnan S
and Ostrowski MC: The ETS family of oncogenic transcription factors
in solid tumours. Nat Rev Cancer. 17:337–351. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ryland GL, Hunter SM, Doyle MA, Caramia F,
Li J, Rowley SM, Christie M, Allan PE, Stephens AN, Bowtell DD, et
al: Mutational landscape of mucinous ovarian carcinoma and its
neoplastic precursors. Genome Med. 7:872015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yeung TL, Leung CS, Wong KK,
Gutierrez-Hartmann A, Kwong J, Gershenson DM and Mok SC: ELF3 is a
negative regulator of epithelial-mesenchymal transition in ovarian
cancer cells. Oncotarget. 8:16951–16963. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang JL, Chen ZF, Chen HM, Wang MY, Kong
X, Wang YC, Sun TT, Hong J, Zou W, Xu J and Fang JY: Elf3 drives
β-catenin transactivation and associates with poor prognosis in
colorectal cancer. Cell Death Dis. 5:e12632014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng L, Xu M, Xu J, Wu K, Fang Q, Liang
Y, Zhou S, Cen D, Ji L, Han W and Cai X: ELF3 promotes
epithelial-mesenchymal transition by protecting ZEB1 from
miR-141-3p-mediated silencing in hepatocellular carcinoma. Cell
Death Dis. 9:3872018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res.
45W:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nagy Á, Lánczky A, Menyhárt O and Győrffy
B: Validation of miRNA prognostic power in hepatocellular carcinoma
using expression data of independent datasets. Sci Rep. 8:92272018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sharrocks AD: The ETS-domain transcription
factor family. Nat Rev Mol Cell Biol. 2:827–837. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Flentjar N, Chu PY, Ng AY, Johnstone CN,
Heath JK, Ernst M, Hertzog PJ and Pritchard MA: TGF-betaRII rescues
development of small intestinal epithelial cells in Elf3-deficient
mice. Gastroenterology. 132:1410–1419. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oliver JR, Kushwah R, Wu J, Pan J, Cutz E,
Yeger H, Waddell TK and Hu J: Elf3 plays a role in regulating
bronchiolar epithelial repair kinetics following Clara
cell-specific injury. Lab Invest. 91:1514–1529. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Böck M, Hinley J, Schmitt C, Wahlicht T,
Kramer S and Southgate J: Identification of ELF3 as an early
transcriptional regulator of human urothelium. Dev Biol.
386:321–330. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang H, Yu Z, Huo S, Chen Z, Ou Z, Mai J,
Ding S and Zhang J: Overexpression of ELF3 facilitates cell growth
and metastasis through PI3K/Akt and ERK signaling pathways in
non-small cell lung cancer. Int J Biochem Cell Biol. 94:98–106.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ojesina AI, Lichtenstein L, Freeman SS,
Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio
L, Cibulskis K, Bertelsen B, et al: Landscape of genomic
alterations in cervical carcinomas. Nature. 506:371–375. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo G, Sun X, Chen C, Wu S, Huang P, Li Z,
Dean M, Huang Y, Jia W, Zhou Q, et al: Whole-genome and whole-exome
sequencing of bladder cancer identifies frequent alterations in
genes involved in sister chromatid cohesion and segregation. Nat
Genet. 45:1459–1463. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Longoni N, Sarti M, Albino D, Civenni G,
Malek A, Ortelli E, Pinton S, Mello-Grand M, Ostano P, D'Ambrosio
G, et al: ETS transcription factor ESE1/ELF3 orchestrates a
positive feedback loop that constitutively activates NF-κB and
drives prostate cancer progression. Cancer Res. 73:4533–4547. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yachida S, Wood LD, Suzuki M, Takai E,
Totoki Y, Kato M, Luchini C, Arai Y, Nakamura H, Hama N, et al:
Genomic sequencing identifies ELF3 as a driver of ampullary
carcinoma. Cancer Cell. 29:229–240. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Murugan AK: mTOR: Role in cancer,
metastasis and drug resistance. Semin Cancer Biol. 59:92–111. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Agarwal R and Kaye SB: Ovarian cancer:
Strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li SS, Ma J and Wong AST: Chemoresistance
in ovarian cancer: Exploiting cancer stem cell metabolism. J
Gynecol Oncol. 29:e322018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Islam SS and Aboussekhra A: Sequential
combination of cisplatin with eugenol targets ovarian cancer stem
cells through the Notch-Hes1 signalling pathway. J Exp Clin Cancer
Res. 38:3822019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ai Z, Lu Y, Qiu S and Fan Z: Overcoming
cisplatin resistance of ovarian cancer cells by targeting
HIF-1-regulated cancer metabolism. Cancer Lett. 373:36–44. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li X, Chen W, Jin Y, Xue R, Su J, Mu Z, Li
J and Jiang S: MiR-142-5p enhances cisplatin-induced apoptosis in
ovarian cancer cells by targeting multiple anti-apoptotic genes.
Biochem Pharmacol. 161:98–112. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rada M, Nallanthighal S, Cha J, Ryan K,
Sage J, Eldred C, Ullo M, Orsulic S and Cheon DJ: Inhibitor of
apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven
cisplatin resistance in ovarian cancer. Oncogene. 37:4809–4820.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gong T, Cui L, Wang H, Wang H and Han N:
Knockdown of KLF5 suppresses hypoxia-induced resistance to
cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis
through inactivation of the PI3K/Akt/mTOR pathway. J Transl Med.
16:1642018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wantoch von Rekowski K, König P, Henze S,
Schlesinger M, Zawierucha P, Januchowski R and Bendas G: Insight
into cisplatin-resistance signaling of W1 ovarian cancer cells
emerges mTOR and HSP27 as targets for sensitization strategies. Int
J Mol Sci. 21:92402020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sheng J, Shen L, Sun L, Zhang X, Cui R and
Wang L: Inhibition of PI3K/mTOR increased the sensitivity of
hepatocellular carcinoma cells to cisplatin via interference with
mitochondrial-lysosomal crosstalk. Cell Prolif. 52:e126092019.
View Article : Google Scholar : PubMed/NCBI
|
